Notably, two molecules that have been shown to preferentially decrease the expression of GRP78 in tumor cells and ER-stressed cells when compared to normal cells, BOLD-100 and NKP-1339, are being tested in phase I clinical trials in CRC patients. Here, HSPA5 is linked to colorectal carcinoma.